Fig. 3: CXCL7 Mediates Tumor Chemotherapy Resistance in vivo. | Cell Death & Disease

Fig. 3: CXCL7 Mediates Tumor Chemotherapy Resistance in vivo.

From: Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization

Fig. 3

A Representative images and body weights of mice injected with CXCL7 + Mø or CXCL7- Mø under 5-FU/oxaliplatin treatment (n = 5 mice per group). B CT26 tumor growth in immunocompetent BALB/c mice treated with control or macrophage depletion (n = 5 mice per group). C CXCL7 expression levels in macrophage-intact versus macrophage-depleted tumors analyzed by RT-qPCR. D IHC staining of CD11b+ cells and CXCL7+ expression in control versus clodronate-treated tumors (scale bar, 50 μm). E CT26 tumor progression in mice treated with isotype control or CXCL7-neutralizing antibodies (n = 5 mice per group). F TUNEL-positive cells and representative IHC images of CXCL7 in the tumors obtained from mice treated with isotype control or CXCL7 neutralizing antibodies (scale bar for TUNEL, 10 μm; scale bar for IHC, 100 μm). G Intestinal polyp quantification (number/size) and representative images from AOM/DSS mice treated with control or CXCL7-neutralizing antibodies (scale bar, 100 μm). H HE and IHC detection of CXCL7 expression across different groups of mice, as indicated (scale bar, 100 μm). I TUNEL+ apoptotic cell counts in AOM/DSS mice with/without CXCL7 antibody treatment. All data are presented as mean ± SD. *P < 0.05; n.s.not significant.

Back to article page